Last reviewed · How we verify
Vonoprazan-based triple therapy
Vonoprazan-based triple therapy, marketed by Fu Jen Catholic University Hospital, holds a position in the treatment landscape for its indicated use, though specific details on its primary indication and revenue are not provided. A key strength of this therapy is its patent protection, which extends until 2028, providing a period of market exclusivity. The primary risk is the lack of detailed clinical trial results and competitor information, which may affect its market positioning and adoption.
At a glance
| Generic name | Vonoprazan-based triple therapy |
|---|---|
| Also known as | VAC-7 |
| Sponsor | Fu Jen Catholic University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (PHASE3)
- Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection (NA)
- Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management (PHASE4)
- 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vonoprazan-based triple therapy CI brief — competitive landscape report
- Vonoprazan-based triple therapy updates RSS · CI watch RSS
- Fu Jen Catholic University Hospital portfolio CI